{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:16:19Z","timestamp":1778220979361,"version":"3.51.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Autosomal dominant hypocalcemia type 1 (ADH1) is a rare inherited disorder caused by gain-of-function mutations in the calcium-sensing receptor (\n                      <jats:italic>CASR<\/jats:italic>\n                      ) gene, with clinical manifestations ranging from asymptomatic hypocalcemia to recurrent seizures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical evaluation and genetic testing were performed. Through activation of the MAPK signaling pathway,cellular functional validation was conducted to confirm the pathogenicity of this variant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We report a two-generation family in which the proband presented with lifelong recurrent convulsive episodes and was misdiagnosed with epilepsy for decades, resulting in persistent symptoms despite antiepileptic therapy. His son exhibited similar manifestations. A whole-exome sequencing (WES) analysis was identified a previously unreported heterozygous\n                      <jats:italic>CASR<\/jats:italic>\n                      mutation, c.2452T&amp;gt;C (p.Trp818Arg). Functional cellular analyses confirmed that it caused a novel gain-of-function\n                      <jats:italic>CASR<\/jats:italic>\n                      mutant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the critical role of genetic testing in the diagnosis of ADH1, particularly in patients with recurrent seizures or neonatal hypocalcemia with hyperphosphatemia and normal renal function. Once the diagnosis is established, treatment options for symptomatic patients include calcium supplementation and calcitriol, aiming to maintain serum calcium at the lower end of the reference range and relieve symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1806677","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:27Z","timestamp":1778219787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel gain-of-function mutation (W818R) of calcium-sensing receptor in a family with autosomal dominant hypocalcemia type 1"],"prefix":"10.3389","volume":"17","author":[{"given":"Min","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Department of Endocrinology, Wuhan Third Hospital","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxiang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Peking University Fifth School of Clinical Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kexin","family":"Xu","sequence":"additional","affiliation":[{"name":"Center for Human Genome Research, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Peking University Fifth School of Clinical Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Peking University Fifth School of Clinical Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1215036","article-title":"Case report: Calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations","volume":"14","author":"Ali","year":"2023","journal-title":"Front Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.04.006","article-title":"Familial hypocalciuric hypercalcemia type 1 and autosomal-dominant hypocalcemia type 1: prevalence in a large healthcare population","volume":"106","author":"Dershem","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","article-title":"The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases","volume":"15","author":"Hannan","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4659","article-title":"Autosomal dominant hypocalcemia type 1: a systematic review","volume":"37","author":"Roszko","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02496-y","article-title":"Management of autosomal dominant hypocalcemia type 1: literature review and clinical practice recommendations","volume":"48","author":"De Coster","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.1.23","article-title":"Search for novel mutational targets in human endocrine diseases","volume":"34","author":"Park","year":"2019","journal-title":"Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgae769","article-title":"CASRdb: a publicly accessible comprehensive database for disease-associated calcium-sensing receptor variants","volume":"110","author":"Charoenngam","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00223-025-01414-5","article-title":"Consensus-based recommendations for the diagnosis, treatment, and monitoring of hypoparathyroidism: insights from the DACH region","volume":"116","author":"Tsourdi","year":"2025","journal-title":"Calcif Tissue Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-008-0067-9","article-title":"Hypocalcemia in the newborn","volume":"75","author":"Jain","year":"2008","journal-title":"Indian J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3283591502","article-title":"Hypoparathyroidism: from diagnosis to treatment","volume":"19","author":"De Sanctis","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2010.010139","article-title":"Four cases of autosomal dominant hypocalcemia with hypercalciuria including two with novel mutations in the calcium-sensing receptor gene","volume":"48","author":"Schouten","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07055-2","article-title":"Allosteric modulation and G-protein selectivity of the Ca(2+)-sensing receptor","volume":"626","author":"He","year":"2024","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg1483","article-title":"Structural basis for activation and allosteric modulation of full-length calcium-sensing receptor","volume":"7","author":"Wen","year":"2021","journal-title":"Sci Adv"},{"key":"B16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/ejendo\/lvae035","article-title":"Functional evaluation of a novel nonsense variant of the calcium-sensing receptor gene leading to hypocalcemia","volume":"190","author":"Saglia","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy263","article-title":"Calcium-sensing receptor residues with loss- and gain-of-function mutations are located in regions of conformational change and cause signaling bias","volume":"27","author":"Gorvin","year":"2018","journal-title":"Hum Mol Genet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/eje-15-1216","article-title":"Novel calcium-sensing receptor cytoplasmic tail deletion mutation causing autosomal dominant hypocalcemia: molecular and clinical study","volume":"174","author":"Obermannova","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41467-022-29897-y","article-title":"Mechanism of sensitivity modulation in the calcium-sensing receptor via electrostatic tuning","volume":"13","author":"Schamber","year":"2022","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf222","article-title":"Revised European Society of Endocrinology clinical practice guideline: treatment of chronic hypoparathyroidism in adults","volume":"193","author":"Bollerslev","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.07.009","article-title":"Hypoparathyroidism and the kidney","volume":"47","author":"Peacock","year":"2018","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1800213","article-title":"Hypoparathyroidism","volume":"380","author":"Gafni","year":"2019","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.10.5185","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1\u201334 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2034981","article-title":"PTH infusion for seizures in autosomal dominant hypocalcemia type 1","volume":"385","author":"Sastre","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3747","article-title":"Treatment of autosomal dominant hypocalcemia type 1 with the calcilytic NPSP795 (SHP635)","volume":"34","author":"Roberts","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.07.044","article-title":"A novel chemoreactive calcilytic for the potential treatment of autosomal dominant hypocalcemia","volume":"15","author":"Dangerfield","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108404","article-title":"Characterization of quinazolinone calcilytic therapy for autosomal dominant hypocalcemia type 1 (ADH1)","volume":"301","author":"Hannan","year":"2025","journal-title":"J Biol Chem"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1806677\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:28Z","timestamp":1778219788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1806677\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":31,"alternative-id":["10.3389\/fendo.2026.1806677"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1806677","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1806677"}}